Pfizer's oncology revenues jumped 30 percent in the third quarter, with growth from several precision oncology drugs.

In a Phase III trial, more patients on Scemblix had a major molecular response than on investigator-selected tyrosine kinase inhibitors.

The financing will allow the firm to further develop its AI platform, develop drugs in best responders, and acquire new pipeline candidates.

The FDA had asked for more chemistry, manufacturing, and controls information after reviewing an earlier BLA on the investigational therapy.

NEW YORK – Novartis is gearing up to meet a threefold growth in patient demand for Pluvicto (vipivotide tetraxetan), betting ...

The partners are also studying their personalized vaccine with Keytruda as an adjuvant NSCLC treatment for those who haven't gotten neoadjuvant therapy.

The companies have plans to evaluate IDE275 as a monotherapy and combined with immunotherapy in MSI-high solid tumors.

Through the acquisition, AbbVie will gain Aliada's lead asset, a beta-amyloid-targeting drug in a Phase I trial designed to cross the blood-brain barrier.

The efficacy seen in a small study, especially in GNAS-mutated tumors, could influence care, but the rarity of the cancer is ...

The firm will stop developing several of its own cell therapies to focus on advancing IMPT-314, a CAR T-cell therapy it is gaining by purchasing ImmPact.

The firm will use the funds to advance its pipeline of radiopharmaceutical agents, including an imaging agent currently being studied in melanoma.

The partners will use Pangea's ENLIGHT-DP platform to analyze data from two clinical studies at OHSU and improve understanding to tumor resistance and response.